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Transfusion related acute 
lung injury (TRALI)
ABSTRACT
Transfusion-related acute lung injury (TRALI) is a complication following transfusion of blood products and is potentially a 
life-threatening adverse event of transfusion. The first case of fatal pulmonary edema following transfusion was reported in 
the 1950s. In recent time, TRALI has developed from an almost unknown transfusion reaction to the most common cause 
of transfusion related major morbidities and fatalities. A clinical definition of TRALI was established in 2004, based on acute 
respiratory distress which has temporal association with transfusion of blood components. In 2008 a distinction between 
classic and delayed syndrome was proposed. However, pathophysiology of TRALI still remains controversial. A number of 
different models were proposed to explain the pathogenesis. The two, presently most accepted models, are not mutually 
exclusive. The first is the antibody mediated model and the second is the two-event model.
In this review article the definition of TRALI, patient predisposition, treatment, prevention and reporting guidelines are exa-
mined. The current knowledge on the topic TRALI is summarized.
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Introduction
Transfusion-related acute lung injury 
(TRALI) is one of the most common 
causes of transfusion associated major 
morbidity and death. The results from 
many national haemovigillance pro-
grams have identified TRALI as a signi-
ficant adverse event of transfusion, and 
the reported mortality rates vary from 5 
to 25%. (1-5) TRALI is a life-threatening 
adverse event of transfusion.
Investigators have shown that non-cardi-
ogenic lung edema is also an important 
pulmonary complication of transfusi-
on. Since Barnard’s initial description in 
1951, (6) non-cardiogenic lung edema 
related to transfusion has been widely 
reported using various names, including 
non-cardiogenic pulmonary edema, 
pulmonary hypersensitivity and seve-
re allergic pulmonary edema. In 1983 
Popovsky et al. (7,8) coined the term 
"transfusion-related acute lung injury". 
The true incidence of TRALI is unknown 
but different estimates have been made. 
TRALI has been reported from all types 
of blood components including whole 
blood, red cells, aphaeresis platelets, 
whole blood platelets, fresh frozen 
plasma, cryoprecipitate, granulocytes, 
stem cell products and even IV immu-
noglobulin preparations. (9-13)
According to the literature, the inciden-
ce is 1:5000 for blood components 
(8) with subsequent reports ranging 
from 1:432 for whole blood platelets to 
1:557,000 for red cells. (14) The most 
implicated are plasma-rich compo-
nents, such as plasma and aphaeresis 
platelets. (14,15)
TRALI is under- diagnosed and under- 
reported as many clinicians are not 
familiar with the syndrome. This is equ-
ally true for severe cases of TRALI where 
transfusion may not be considered as a 
possible cause and may be regarded 
as acute respiratory distress syndrome 
(ARDS) but also for mild case where 
mechanical ventilation is not required. 
TRALI can be misdiagnosed as TACO 
(Transfusion Associated Circulatory 
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Overload) as occurred in the French 
haemovigilance network. (2)
Patients who are at risk for developing 
TRALI are still not properly identified.
Van Buren et al. first postulated that 
the clinical status of the patient played 
a significant role in the pathogene-
sis of TRALI. (16) According to some 
observations, patients in the induction 
phase of treatment for hematological 
malignancies and patients with cardio-
vascular disease who required bypass 
surgery have a higher risk for develo-
ping TRALI. (13)
Clinical presentation
TRALI is a clinical syndrome characte-
rized by the acute onset of respiratory 
distress in a patient who received tran-
sfusion. It can present with a variety of 
symptoms and signs, most commonly 
worsening of respiratory function. Pati-
ents present with respiratory distress 
(dyspnea, tachypnea), hypoxia, hypo-
tension (less commonly hypertensi-
on), fever, tachycardia and cyanosis, 
pulmonary edema (frothy pulmonary 
secretions), and bilateral fluffy infiltrates 
on chest radiograph. The majority of 
cases occur during or within 1 to 2 h of 
transfusion. (8)
Definition
The lack of a consensus definition of 
TRALI contributed to its under-reco-
gnition.
The TRALI definition of the Europe-
an Haemovigilance Network (17) and 
Amendments by the TRALI Consensus 
Conference Committee in Toronto in 
2004 (17,18) is:
(a) Acute onset of acute lung injury 
(ALI)
(b) Hypoxemia (PaO2/FiO2 (ratio of 
partial pressure of arterial O2 to the 
fraction of inspired O2) 300 and 
must be adjusted downward with 
increasing altitude or SpO290% 
on room air or other clinical evi-
dence)
(c) Bilateral lung infiltrates on frontal 
chest radiograph
(d) No evidence of left atrial hyperten-
sion (i.e., transfusion-associated 
circulatory overload)
(e) Occurrence during or within 6 h 
after completion of transfusion
(f) No temporal relationship to an alter-
native risk factor for ALI
(g) New ALI and no other ALI risk fac-
tors present including aspiration, 
multiple trauma, pneumonia, car-
diopulmonary bypass, burn injury, 
toxic inhalation, lung contusion, 
acute pancreatitis, drug overdose, 
near drowning, shock and sepsis
(h) If one or more ALI risk factors are 
present, possible TRALI should be 
diagnosed (in patients with an alter-
native ALI risk factor, TRALI is still 
possible)
Classic TRALI is therefore a clinical 
syndrome. Sometimes, a single unit of 
blood or blood product is implicated 
in causing the syndrome. Patients with 
classic TRALI should not have other risk 
factors for ALI and, thus, the transfusion 
is the only identifiable cause of the res-
piratory failure. (19)
Limitations to this definition are the exc-
lusion of patients with preexisting ALI 
and cases with onset more than 6 h 
after transfusion. The modified criteria 
broadened the definition of hypoxia to 
include clinical evidence of hypoxia and 
created a category of “possible TRALI” 
to address cases in which patients have 
other risk factors for ALI such as sepsis, 
aspiration, near-drowning, dissemina-
ted intravascular coagulation, trauma, 
pneumonia, drug overdose, fracture, 
burns and cardiopulmonary bypass. 
(6) In recent years the term "delayed 
TRALI syndrome" emerged. (19) These 
patients usually have other risk factors 
for ARDS and do not meet the current 
definition for TRALI. (17,18)
Characteristics of the “classic TRALI 
syndrome” are: time of onset within 
2 hours (usually up to 6 hours); rapid 
development; no other risk factors for 
ALI except transfusion; anti-neutrophil 
antibodies pathophysiology and onset 
after a single unit of blood product.
Characteristics of the “delayed TRALI 
syndrome” are: time of onset 6-72 
hours after transfusion; slow develo-
pment of clinical presentation; pati-
ents have other risk factors for ALI (i.e. 
sepsis, aspiration, near-drowning, dis-
seminated intravascular coagulation, 
trauma, pneumonia, drug overdose, 
fracture, burns and cardiopulmonary 
bypass); two- step pathophysiology 
and common after massive transfusion 
(40-57%). (19) This distinction is impor-
tant, but undoubtedly there is some 
overlap between the two syndromes.
Differential diagnosis
The differential diagnosis includes 
TACO, cardiogenic edema, allergic and 
anaphylactic transfusion reactions, and 
transfusion of bacterially contaminated 
blood components, and classic ALI. 
Pathophysiology
The exact mechanism of TRALI is still 
not fully understood. (19) At present we 
know that the common denominator is 
the end of the pathway which presents 
with increased pulmonary capillary per-
meability, and results in movement of 
plasma into the alveolar space causing 
pulmonary edema. Two possible theo-
ries have been proposed to explain the 
pathogenesis of TRALI. The first sug-
gests an antibody mediated reaction 
after transfusion. The antibody-medi-
ated model postulates that the reacti-
on is secondary to passive transfusion 
of specific donor antibodies against 
recipient antigens (human leukocyte 
antigen (HLA) specific, mostly HLA-A2 
or anti-granulocyte specific antibodies 
like human neutrophil antigen (HNA)-1a, 
-1b, -3a or HLA 1) or infusion of donor 
antigens (leucocytes) in recipient who 
already has antibodies against them. 
This antibody-antigen interaction can 
cause complement activation, resul-
ting in the pulmonary sequestration and 
activation of neutrophils, endothelial cell 
damage, and a capillary leak syndro-
me in the lungs manifesting as TRALI. 
(10,17-19) There is evidence that TRALI 
is more common in recipients of blood 
products from multiparous female 
donors who are more likely to possess 
anti-HLA antibodies and anti–neutrop-
hil-specific antibodies. (20) However, in 
about 5-15% of cases, no antibody is 
identified in either the donor or recipi-
ent. The second is a two-event model. 
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(13,18-20) The first event (first hit) is the 
clinical condition of the patient resulting 
in pulmonary endothelial activation and 
polimorphonuclear (PMN) sequestra-
tion, and the second event is the tran-
sfusion of a biologic response modifier 
(including anti-granulocyte antibodies, 
lipids, and CD40 ligand) that activa-
tes these adherent PMNs resulting in 
endothelial damage, capillary leak, and 
TRALI. These two mechanisms of injury 
may not be mutually exclusive and a 
patient may develop TRALI through eit-
her one or both mechanisms. 
Prevention
TRALI prevention is a complex issue, 
and comprehensive and effective 
preventive treatment steps are still 
unknown. (19,21) Although it is prob-
ably impossible to prevent all cases of 
TRALI, there are certain measures that 
can be taken to at least prevent TRALI 
as much as possible.
Specific measures that could be con-
sidered in critical care practice include 
better compliance with evidence based 
triggers for transfusion, greater use of 
near patient testing to determine the 
need for transfusion, and minimizing 
blood loss due to sampling. 
All TRALI reactions should be reported 
to the transfusion service. All associated 
donors are tested for HLA class I and II 
antibodies as well as HNA antibodies. 
As the transfused units are usually not 
available for testing, this involves recall-
ing the donors. Associated donors may 
continue donating while being inves-
tigated but only plasma for fraction-
ation is used. All implicated donors (i.e. 
donors who are cross match positive 
with the patient’s leucocytes or donors 
who have the cognate antibody to HLA 
class I, II or neutrophil antigens of the 
patient) are permanently deferred from 
donation. The permanent deferral is 
considered consistent with the 2004 
consensus conference statement (21) 
and is supported by two retrospective 
studies that showed that a TRALI-impli-
cated donor may cause multiple trans-
fusion reactions in different recipients. 
Management of the patient
The management of both the classic 
and delayed TRALI syndrome is essen-
tially supportive and includes gentle 
ventilation (lung protective ventilation).
Conclusion
Further work is required to define: 1) 
the effects of this life threatening syn-
drome; 2) patients who are at risk of 
TRALI and 3) a consensus international 
definition so that clinicians may prop-
erly diagnose TRALI.
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